Its lead candidate, pemvidutide, is being evaluated in multiple indications, including metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder, and alcohol-associated liver disease
Many patients in medically supervised programs not only lose weight but also see improvements in related health issues, such as type 2 diabetes, high blood pressure, elevated cholesterol, and sleep apnea
No recommendation for an oral dose reduction due to low body weight in the USA or Australia could be found
It impacts parts of the brain that manage hunger and how full we feel
Histamine intolerance is thought to affect approximately 13% of the population, although exact figures are hard to determine due to diagnostic challenges
Clinical reviews examining nutritional intake patterns in individuals using GLP-1 receptor agonists highlight predictable areas where support may be needed, particularly when reduced intake is sustained over time